Menu
← Oncology Approval Tracker
FDA DECISION ·
Wilserdly + everolimus
giredestrant and everolimus · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Giredestrant with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, identified by an FDA-authorized test, after recurrence during or after adjuvant endocrine-based therapy or progression on a metastatic endocrine-based regimen.
SUPPORTING DATA
Evidence behind the decision
- Study
- evERA: randomized, open-label trial; 373 participants, including 207 with ESR1 mutations.
- Key result
- In the ESR1-mutated population, median progression-free survival was 10 versus 5.5 months against physician-selected endocrine therapy plus everolimus; hazard ratio 0.38 (95% CI 0.27-0.54).
- Safety to report
- FDA reports stomatitis, rash, fatigue, diarrhea and pneumonitis; warnings include bradycardia and embryo-fetal toxicity.
- Evidence limits
- Overall-survival data were immature. The trial does not support cross-trial comparisons with other endocrine combinations.
LAMPGEN ANALYSIS
Why it matters
A new oral endocrine combination for a molecularly selected population. Its approval does not establish benefit in earlier breast cancer settings.
What research teams should watch
Study teams should align ESR1 testing, prior endocrine-treatment records, progression dates and oral-treatment accountability before screening.
PRIMARY RECORDS